Depo-Provera Lawsuit Lawyer

Attorney Michael Gunzburg

The Connection Between Depo-Provera and Meningioma

Multiple peer-reviewed studies have found that women who used Depo-Provera for an extended period face a substantially elevated risk of developing a meningioma. A study published in The BMJ found that women who received the Depo-Provera shot for more than one year were approximately 5.5 times more likely to develop a meningioma than non-users.  A separate study published in JAMA Neurology identified an approximately twofold increased risk among Depo-Provera users.

A meningioma is a tumor that forms in the meninges, the layers of tissue that cover the brain and spinal cord. Most are non-cancerous, but depending on size and location, a meningioma can cause serious, sometimes permanent neurological harm, including vision loss, seizures, and cognitive changes, and often requires surgery or radiation to treat.

Meningioma risk connected to Depo-Provera use is dose- and duration-dependent. The longer and more frequently a woman received the injection, generally administered every 12 to 13 weeks, the higher the documented risk. This duration relationship is central to how eligibility is currently being evaluated across the litigation.

Where the Litigation Stands Now

A global settlement in principle was reached on June 15, 2026, but it is not final and does not resolve every case. [Review for accuracy — time-sensitive claim, confirm status before publishing and at each subsequent review] The claims are consolidated in federal court as In re: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, before Judge M. Casey Rodgers in the U.S. District Court for the Northern District of Florida, Pensacola Division. As of court filings in mid-2026, more than 5,500 federal cases were pending in the MDL, making it one of the largest active pharmaceutical mass torts in the country.

The June 15 order confirmed that Pfizer and plaintiffs' leadership reached an agreement that would give eligible plaintiffs with cases already pending in the MDL an opportunity to resolve their claims. In response, the court vacated the trial schedule for the first bellwether case, which had been set for December 7, 2026. The financial terms of the agreement have not been made public, and the agreement does not automatically cover every claim, including many state-court cases filed outside the MDL, such as those pending in New York and Delaware courts.

This means the practical picture for someone recently diagnosed is more nuanced than either "the case is over" or "nothing has happened." A claim can generally still be filed, and where it is filed and how it is positioned relative to the global agreement can affect a woman's options.

FDA Warning and What It Means for a Claim

In December 2025, the FDA approved a label change for Depo-Provera CI and Depo-SubQ Provera 104 adding a specific meningioma warning, after initially denying a similar request from Pfizer in 2024.  The approved warning language states that meningiomas have been reported following repeated administration of medroxyprogesterone acetate, primarily with long-term use, and instructs physicians to monitor patients for signs of meningioma and to discontinue the drug if one is diagnosed, as reported by NBC News.

Court filings indicate Pfizer became aware of a possible meningioma link as early as 2023 and first sought a label change in February 2024, a request the FDA denied at the time. Pfizer resubmitted its application in June 2025 with additional data, and the FDA approved the warning in December 2025. This timeline, the gap between when the company reportedly knew and when patients were warned, is central to the failure-to-warn claims at the core of this litigation. Canada and the European Union had already required similar warnings on Depo-Provera labeling since 2022. Women who suspect a connection between their diagnosis and Depo-Provera use, or who want more background on the case, can read what one Depo-Provera victim's lawsuit against the manufacturer looked like and an overview of the legal battle over Depo-Provera and brain tumors.

Who Qualifies for a Depo-Provera Brain Tumor Claim

Eligibility for a Depo-Provera lawsuit generally comes down to three things:

• Documented use. Depo-Provera use, specifically the injection form rather than an oral contraceptive, confirmed through prescription, pharmacy, or provider records, typically for one year or longer.
• A confirmed diagnosis. A meningioma diagnosis, specifically intracranial meningioma, supported by MRI imaging and, where available, pathology reports.
• A timeline that fits. A diagnosis occurring during or after the period of Depo-Provera use, without a clear, more likely alternative cause.

You do not need every document in hand to start. An attorney can typically help track down prescription records, imaging, and pathology reports as part of building the case, so incomplete records are a reason to call, not a reason to wait.

Duration generally matters. The longer and more consistent the Depo-Provera use, the stronger the documented risk connection, though gaps in use or a shorter history do not automatically disqualify a claim. Some common factors that can complicate a claim, without necessarily ruling it out, include a meningioma diagnosed before starting Depo-Provera, a documented family history of meningioma unrelated to medication use, or very short-term or inconsistent use. These are exactly the kind of case-specific questions a free case evaluation is designed to sort through, not something to self-diagnose from a website.

What Compensation May Cover

Eligibility for a Depo-Provera lawsuit generally comes down to three things:

• Documented use. Depo-Provera use, specifically the injection form rather than an oral contraceptive, confirmed through prescription, pharmacy, or provider records, typically for one year or longer.
• A confirmed diagnosis. A meningioma diagnosis, specifically intracranial meningioma, supported by MRI imaging and, where available, pathology reports.
• A timeline that fits. A diagnosis occurring during or after the period of Depo-Provera use, without a clear, more likely alternative cause.

You do not need every document in hand to start. An attorney can typically help track down prescription records, imaging, and pathology reports as part of building the case, so incomplete records are a reason to call, not a reason to wait.

Duration generally matters. The longer and more consistent the Depo-Provera use, the stronger the documented risk connection, though gaps in use or a shorter history do not automatically disqualify a claim. Some common factors that can complicate a claim, without necessarily ruling it out, include a meningioma diagnosed before starting Depo-Provera, a documented family history of meningioma unrelated to medication use, or very short-term or inconsistent use. These are exactly the kind of case-specific questions a free case evaluation is designed to sort through, not something to self-diagnose from a website.

How Michael Gunzburg, P.C. Can Help

Several large national firms and Depo-Provera lawsuit lawyers are actively advertising for these claims and processing high volumes of intake. Michael Gunzburg, P.C. takes a different approach: a smaller caseload where each client's medical history, financial losses, and legal options get individual attention rather than a standardized script. That combination, trial experience built over 39+ years in New York courts paired with CPA-level financial analysis, is not something every mass-tort intake firm can offer. Representation is handled on a contingency-fee basis, so there is no upfront cost to have a case evaluated, and no fee unless the firm recovers compensation.

The firm's litigation experience spans complex, multi-party cases across personal injury and product liability matters, including other pharmaceutical and consumer-product injury claims such as the firm's Dupixent CTCL litigation and its nationwide nitrous oxide injury cases. Case results across the firm's broader practice are available on the verdicts and settlements page, and background on the firm's trial experience and credentials is available on Michael Gunzburg's attorney profile and the firm's about page.

Key Takeaways

• A global settlement in principle in the Depo-Provera MDL was reached on June 15, 2026, but the terms are not public and the agreement does not resolve every pending claim.
• The FDA approved a meningioma-specific warning label for Depo-Provera in December 2025, after initially denying the same request in 2024.
• Peer-reviewed research found up to a 5.5-fold increased meningioma risk in women who used Depo-Provera for more than one year.
• Claims are consolidated in MDL No. 3140 before Judge M. Casey Rodgers in the Northern District of Florida, with more than 5,500 federal cases pending as of mid-2026.
• Michael Gunzburg, P.C. evaluates Depo-Provera meningioma claims nationwide on a contingency-fee basis, with no fee unless the case results in a recovery.

Common Questions About Depo-Provera Brain Tumor Lawsuits

How do I know if I qualify for a Depo-Provera lawsuit?

Eligibility generally requires documented Depo-Provera use of a year or more, a confirmed meningioma diagnosis supported by imaging, and a diagnosis timeline consistent with drug-related risk rather than a clear alternative cause. Every case is different, and the only reliable way to know is a free, no-obligation case evaluation with an attorney who can review the specific medical and usage history involved.

How much money can you get from a Depo-Provera lawsuit?

No attorney can state a specific settlement amount right now, because the financial terms of the June 2026 global agreement have not been made public.  Compensation in these cases is generally evaluated based on the severity of the diagnosis, treatment required, lost income, and long-term impact, not a flat payout applied to every claim.

Is there really a Depo-Provera settlement, or is the case still open?

Both are true at once. A federal judge confirmed on June 15, 2026, that Pfizer and plaintiffs' lead counsel reached a global agreement in principle, and the first scheduled bellwether trial has been vacated as a result.  However, the agreement is not finalized, its terms are confidential, and it does not automatically cover every case, including many filed in state court. New claims can still generally be evaluated and filed.

What evidence do I need to file a Depo-Provera lawsuit?

The core documentation includes medical or pharmacy records confirming Depo-Provera use and its duration, imaging or pathology records confirming the meningioma diagnosis, and treatment records. If any of these records are incomplete, an attorney can typically help track them down as part of building the case, so missing documentation on day one is not a reason to delay a free consultation.

How far back does the Depo-Provera lawsuit go?

Claims generally cover women who used Depo-Provera and were later diagnosed with a meningioma, regardless of how many years ago the use occurred, though state-specific statutes of limitations affect how long someone has to file after a qualifying diagnosis.  Because deadlines vary and can be easy to miscalculate in a case involving a years-long exposure period, it is worth confirming your specific timeline with an attorney rather than assuming you are out of time.

Do I have to go to court for a Depo-Provera lawsuit?

Most claims in a mass tort like this one resolve through negotiated settlement rather than an individual trial, particularly now that a global agreement in principle is in place. A small number of bellwether cases are selected to go through trial to help set values for the broader litigation, but the large majority of plaintiffs are not personally required to testify in open court.

What if I'm not sure I qualify, or I'm missing some of my medical records?

That uncertainty is exactly what a free case evaluation is for. An experienced attorney can review whatever records are available, identify what else may be needed, and help request missing documentation from providers or pharmacies. Being unsure is not a reason to wait, particularly with filing deadlines in play.

How is Michael Gunzburg, P.C. different from a large national mass-tort firm?

Michael Gunzburg, P.C. handles a deliberately smaller caseload, which means direct attorney involvement rather than a call-center intake model. The firm's founding attorney is also a Certified Public Accountant, which brings added precision to calculating lost income and long-term financial impact, a category of damages that is easy to undervalue in a standardized mass-tort process.

Get a Free Depo-Provera Case Evaluation

Every Depo-Provera meningioma case turns on specific medical and usage history, and a free consultation is the fastest way to find out where a case stands. Michael Gunzburg, P.C. reviews Depo-Provera claims nationwide on a contingency-fee basis, so there is no cost to get started and no fee unless the case results in a recovery. Call (212) 725-8500 or reach the firm online today for a confidential case review.